AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease (English only)
Crenezumab did not statistically significantly slow or prevent cognitive decline in people
with a specific genetic mutation which causes early-onset Alzheimer’s disease
Numerical differences favouring crenezumab over placebo were observed across the co-primary,
multiple secondary and exploratory endpoints
Initial data will be presented at the Alzheimer’s Association International Conference (AAIC) on
August 2, 2022
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease.